Ⅰb~Ⅱb期宫颈癌先期化疗疗效研究(1)
[摘要] 目的 探讨Ⅰb～Ⅱb期宫颈癌术前先期治疗疗效。 方法 将我院84例宫颈癌患者分三组，其中，直接手术组28例，静脉化疗组25例，介入化疗组31例。静脉化疗组与介入化疗组在术前均进行先期化疗一疗程再手术，而直接手术组未进行任何处理直接手术治疗。分析三组化疗疗效及并发症情况。 结果 静脉化疗组与介入化疗组宫颈癌肿块缩小在临床分期、肿块大小、病理分类、病理分化方面比较，差异均无统计学意义(P > 0.05)。静脉化疗组与直接手术组不良因素、高危因素比较，差异有统计学意义(P < 0.05)；介入化疗组与直接手术组不良因素、高危因素比较，差异有统计学意义(P < 0.05)。直接手术组术中出血为(682.43±52.75)mL，与静脉化疗组的(557.45±49.28)mL比较，差异无统计学意义(P > 0.05)，与介入化疗组的(704.25±43.57)mL比较，差异无统计学意义(P > 0.05)。直接手术组并发症发生率与静脉化疗组及介入化疗组比较，差异均无统计学意义(P > 0.05)。 结论 术前新辅助化疗已广泛应用于Ⅰb～Ⅱb期宫颈癌患者，在实际临床工作中取得了良好效果，不仅能够减少患者预后不良因素，而且对术中出血量无明显影响，术后并发症亦没有明显增加，可以提高患者5年生存率和生活质量。
, http://www.100md.com
[关键词] 宫颈癌；新辅助化疗；介入化疗；静脉化疗；先期治疗
[中图分类号] R737.33 [文献标识码] A [文章编号] 1673-7210(2012)07(b)-0032-03
Research of effects of primary chemotherapy on Ⅰb-Ⅱb stage of cervical cancer
SUN Yaling
The People's Hospital of Zunhua City, Hebei Province, Zunhua 064200, China
[Abstract] Objective To discuss the effects of primary chemotherapy on Ⅰb-Ⅱb stage of cervical cancer. Methods 84 cases of patients with Ⅰb-Ⅱb stage of cervical cancer in our hospital were divided into three groups: direct surgery group (n = 28), venous chemotherapy group (n = 25) and intervention chemotherapy group (n = 31). Patients of the venous chemotherapy group and intervention chemotherapy group all underwent operation after one course of primary chemotherapy.Direct surgery group underwent operation without any processing. The efficacy of chemotherapy and complications among the three groups were compared. Results There were no significant differences in clinical stage, tumor size, histologic classification, pathologic differentiation of tumour reduction between venous chemotherapy group and interventional chemotherapy group (P > 0.05).There were significant differences in adverse factors, risk factors between intervention chemotherapy group and direct surgery group (P < 0.05); there were significant differences in adverse factors and risk factors between venous chemotherapy group and direct surgery group (P < 0.05). There was no significant difference in amount of bleeding between direct surgery group [(682.43±52.75) mL] and venous chemotherapy group [(557.45±49.28) mL] (P > 0.05) or interventional chemotherapy group [(704.25±43.57) mL] (P > 0.05). There was no significant difference in the incidence of complications between direct surgery group and venous chemotherapy group or interventional chemotherapy group (P > 0.05). Conclusion Preoperative neoadjuvant chemotherapy has been widely used in Ⅰb-Ⅱb stage of patients with cervical cancer and achieves good results in actual clinical work. It not only can reduce the prognosis adverse factors, but also has no significant effect on intraoperative blood loss and postoperative complications. It can improve 5-years survival rate and patients' quality of life., 百拇医药(孙亚玲)
, http://www.100md.com
[关键词] 宫颈癌；新辅助化疗；介入化疗；静脉化疗；先期治疗
[中图分类号] R737.33 [文献标识码] A [文章编号] 1673-7210(2012)07(b)-0032-03
Research of effects of primary chemotherapy on Ⅰb-Ⅱb stage of cervical cancer
SUN Yaling
The People's Hospital of Zunhua City, Hebei Province, Zunhua 064200, China
[Abstract] Objective To discuss the effects of primary chemotherapy on Ⅰb-Ⅱb stage of cervical cancer. Methods 84 cases of patients with Ⅰb-Ⅱb stage of cervical cancer in our hospital were divided into three groups: direct surgery group (n = 28), venous chemotherapy group (n = 25) and intervention chemotherapy group (n = 31). Patients of the venous chemotherapy group and intervention chemotherapy group all underwent operation after one course of primary chemotherapy.Direct surgery group underwent operation without any processing. The efficacy of chemotherapy and complications among the three groups were compared. Results There were no significant differences in clinical stage, tumor size, histologic classification, pathologic differentiation of tumour reduction between venous chemotherapy group and interventional chemotherapy group (P > 0.05).There were significant differences in adverse factors, risk factors between intervention chemotherapy group and direct surgery group (P < 0.05); there were significant differences in adverse factors and risk factors between venous chemotherapy group and direct surgery group (P < 0.05). There was no significant difference in amount of bleeding between direct surgery group [(682.43±52.75) mL] and venous chemotherapy group [(557.45±49.28) mL] (P > 0.05) or interventional chemotherapy group [(704.25±43.57) mL] (P > 0.05). There was no significant difference in the incidence of complications between direct surgery group and venous chemotherapy group or interventional chemotherapy group (P > 0.05). Conclusion Preoperative neoadjuvant chemotherapy has been widely used in Ⅰb-Ⅱb stage of patients with cervical cancer and achieves good results in actual clinical work. It not only can reduce the prognosis adverse factors, but also has no significant effect on intraoperative blood loss and postoperative complications. It can improve 5-years survival rate and patients' quality of life., 百拇医药(孙亚玲)